Search research articles
Contact Us
Filters
Showing results (41-50 of 60) with videos related to
Page
of 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2018
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Gunther Boysen, Daniel N Rodrigues, Pasquale Rescigno, et al.
Cancer Discovery
|
April 29, 2017
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Jane Goodall, Joaquin Mateo, Wei Yuan, et al.
European Urology
|
May 1, 2019
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer
Adam Sharp, Jon C Welti, Maryou B K Lambros, et al.
European Urology
|
March 24, 2023
Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38]
Christina Guo, Ines Figueiredo, Bora Gurel, et al.
European Urology
|
September 16, 2022
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer
Christina Guo, Ines Figueiredo, Bora Gurel, et al.
Cancer Research
|
April 6, 2021
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer
Alec Paschalis, Jonathan Welti, Antje J Neeb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2018
Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Maryou B Lambros, George Seed, Semini Sumanasuriya, et al.
Nature Cancer
|
July 17, 2023
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells
Daniela Brina, Adele Ponzoni, Martina Troiani, et al.
The Lancet. Oncology
|
December 7, 2019
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Joaquin Mateo, Nuria Porta, Diletta Bianchini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 27, 2026
Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastoma
Crescens Tiu, Wing Yau, Diogo Silva, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 60) with videos related to
Sort By:
Page
of 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2018
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Gunther Boysen, Daniel N Rodrigues, Pasquale Rescigno, et al.
Cancer Discovery
|
April 29, 2017
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Jane Goodall, Joaquin Mateo, Wei Yuan, et al.
European Urology
|
May 1, 2019
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer
Adam Sharp, Jon C Welti, Maryou B K Lambros, et al.
European Urology
|
March 24, 2023
Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38]
Christina Guo, Ines Figueiredo, Bora Gurel, et al.
European Urology
|
September 16, 2022
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer
Christina Guo, Ines Figueiredo, Bora Gurel, et al.
Cancer Research
|
April 6, 2021
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer
Alec Paschalis, Jonathan Welti, Antje J Neeb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2018
Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Maryou B Lambros, George Seed, Semini Sumanasuriya, et al.
Nature Cancer
|
July 17, 2023
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells
Daniela Brina, Adele Ponzoni, Martina Troiani, et al.
The Lancet. Oncology
|
December 7, 2019
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Joaquin Mateo, Nuria Porta, Diletta Bianchini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 27, 2026
Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastoma
Crescens Tiu, Wing Yau, Diogo Silva, et al.
Page
of 6